ArticleBMC gastroenterology2026
A Systemic Inflammation Response Index (SIRI)-based nomogram for predicting the prognosis of hepatitis B virus-related acute-on-chronic liver failure: a retrospective cohort study.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveSystemic inflammatory response is closely linked to the development and prognosis of liver failure. This study aimed to establish a prognostic model incorporating inflammatory markers, including the systemic inflammation response index (SIRI), defined as neutrophil count × monocyte count / lymphocyte count, to assess outcomes in patients with hepatitis B virus–related acute-on-chronic liver failure (HBV-ACLF).
methodsA retrospective analysis was conducted on HBV-ACLF patients admitted to Mengchao Hepatobiliary Hospital of Fujian Medical University from January 2019 to December 2022. Patients were classified by 28-day and 90-day outcomes. Baseline clinical data, hematologic, biochemical, and coagulation parameters were collected. Univariate logistic regression was first performed, followed by multivariate logistic regression with a backward stepwise approach. Model performance was assessed using the area under the receiver operating characteristic curve (AUC), calibration curves, and decision curve analysis.
resultsA total of 321 patients (86.6% male; mean age 46.21 ± 12.46 years) were included, with 28-day and 90-day mortality rates of 16.51% and 24.92%. Non-survivors were older and had higher SBP, SIRI, Cr, BUN, INR, and higher rates of hypertension, decompensated cirrhosis, hepatic encephalopathy, and bacterial infection (all P < 0.05). Multivariate analysis identified SBP, SIRI, Cr, BUN, and INR as independent predictors of both outcomes, while age, lower HDL, and LDL were additionally associated with 90-day mortality. Nomograms showed good calibration and discrimination (AUCs 0.866 and 0.897) and high clinical utility. SIRI remained independently associated with mortality after full adjustment.
conclusionSIRI is significantly associated with the risk of HBV-ACLF mortality, and the nomogram provides an objective tool for identifying high-risk patients and supporting individualized management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.